These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12712230)

  • 1. Therapy for primary pulmonary hypertension.
    McCormack D
    Can Respir J; 2003 Apr; 10(3):169-70. PubMed ID: 12712230
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit.
    Gillis HC; Fischer G; Gupta S
    Am J Health Syst Pharm; 2018 Feb; 75(4):171-172. PubMed ID: 29436464
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The globalization of clinical trials in pulmonary arterial hypertension.
    Park MH; Rubin LJ
    J Heart Lung Transplant; 2010 Feb; 29(2):157-8. PubMed ID: 20113908
    [No Abstract]   [Full Text] [Related]  

  • 5. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
    Ivy DD; Doran A; Claussen L; Bingaman D; Yetman A
    Am J Cardiol; 2004 Apr; 93(7):943-6. PubMed ID: 15050507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
    Bakst AE; Gaine SP; Rubin LJ
    Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
    Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
    J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Lefebvre MC; Hunsche E
    Appl Health Econ Health Policy; 2010; 8(1):69-71; author reply 71-3. PubMed ID: 20238466
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
    Bildirici I; Shumway JB
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex multidrug therapy in a patient with pulmonary hypertension before and after orthotopic heart transplantation. A case report.
    D'Alto M; Alfano D; Maiello C; Sarubbi B; Santoro G; Argiento P; Galdieri N; Russo MG; Cotrufo M; Calabrò R
    J Cardiovasc Med (Hagerstown); 2007 Nov; 8(11):950-2. PubMed ID: 17906484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
    Ishikawa S; Yano S; Wakabayashi K; Tokuda Y; Kobayashi K; Ikeda T; Takeyama H
    Nihon Kokyuki Gakkai Zasshi; 2008 Aug; 46(8):660-6. PubMed ID: 18788437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled epoprostenol.
    Lusardi P; Brown V
    Am J Nurs; 2003 Jul; 103(7):64AA, 64CC, 64EE, 64GG-64HH. PubMed ID: 12865644
    [No Abstract]   [Full Text] [Related]  

  • 16. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
    Kato H; Katori T; Nakamura Y; Kawarasaki H
    Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intravenous administration of a low dose of epoprostenol greatly decreased serum concentrations of endothelin-1 in primary pulmonary hypertension--a case report.
    Kakinuma Y; Honma S; Morimoto T; Maruyama H; Yamazaki A; Ishimitsu T; Yamaguchi I
    Angiology; 2005; 56(5):641-5. PubMed ID: 16193207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion.
    Nagai T; Kohsaka S; Anzai T; Yoshikawa T; Fukuda K; Sato T
    Chest; 2012 Jan; 141(1):272-273. PubMed ID: 22215838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.